Overview

An estimated 1.27 million deaths were attributable to antimicrobial resistance (AMR) in 2019, comparable to the number caused by HIV and AIDs and malaria combined. That makes AMR a leading contributor to global deaths.  

To strengthen AMR surveillance and promote sustainable investments to combat this ongoing crisis, MSH was awarded Phase 2 of The Fleming Fund’s Country Grant to Nigeria. Under the grant, we will work with government and international partners to help the country better monitor for and detect antibiotic-resistant bacteria as well as share and use the resulting data to inform decision-making. The project takes a One Health approach to building the capacity of laboratory systems and improving data management across the human health, animal health, and environment sectors to fight AMR while also providing overall health systems strengthening that aligns with Nigeria’s National Action Plan for AMR.

The grant builds upon accomplishments achieved under Phase 1, which helped increase the quality and quantity of AMR data and made notable contributions to policy and practice changes. MSH will support Phase 2 and focus on the following:

• Production of quality AMR and burden data 

• Quality analyses of data 

• Strengthen the capacity of the health workforce and local institutions  

• Sharing analyses and data with decision-makers  

• Promoting sustainable investment to counter AMR 

The Department of Health and Social Care’s Fleming Fund is the world’s single largest official development assistance investment in global AMR surveillance. It supports up to 25 countries across Africa and Asia in addressing AMR—a leading contributor to deaths from infectious diseases worldwide. The Fleming Fund partners with global organizations to establish and strengthen AMR surveillance systems. This is achieved through a combination of country, regional, and global grants and fellowships to improve areas such as laboratory infrastructure, staff capacity, and data collection and analysis capabilities.